MUHC Vaccine Study Centre

The MUHC Vaccine Study Centre (VSC) conducts vaccine and epidemiological research. Located in Pierrefonds, Quebec, the VSC has conducted over 200 studies with over 8,000 participants enrolled to date.

Want to make a difference? Call 514-624-7855 or text 514-239-7886.

About the MUHC Vaccine Study Centre

Founded in 1991, the MUHC Vaccine Study Centre (VSC) is affiliated with the McGill University Health Centre (MUHC) and the Research Institute of the MUHC (RI-MUHC). The experienced personnel at the VSC conduct vaccine and epidemiological research in collaboration with participants and sponsors. The VSC staff are physicians, nurses and highly trained research personnel, experienced in clinical research and meticulous in their work. They provide a caring, respectful and bilingual environment for study participants.

Our Team

Ongoing Clinical Studies

A Phase I randomized, observer-blind, placebo-controlled trial of a Haemophilus influenzae serotype A (Hia) glycoconjugate vaccine with alum adjuvant in young adults 18 to 40 years of age.
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease

Interested in more information about our studies? Please contact us.

Completed Studies

Pfizer - 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

Medicago - Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

RI-MUHC - COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases (COVIAAD)

MedImmune – A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

Merck - A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

CIHR - COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD)

CIHR - Reinfection in COVID-19 Estimation of Risk: extension

Merck - Efficacy and Safety of MK-1654 in Infants (MK-1654-004)

Moderna - Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children

Contact the MUHC Vaccine Study Centre

For more information about the MUHC Vaccine Study Centre and to learn more about participating in studies at the VSC:

Phone: 514-624-7855

Text: 514-239-7886

Email: coordinators.vsc@muhc.mcgill.ca

Visit: 14770 Pierrefonds Blvd., unit 204, Pierrefonds, Quebec H9H 4Y6

Useful Links

The MUHC Vaccine Study Centre is proud to collaborate with other vaccine research centres and networks across Canada.